---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-061375"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-19T00:11:33.420770+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Positive Phase 1b firmonertinib data; 16.0 mo mPFS at 240 mg; global Phase 3 ALPACCA planned H2 2025

## Summary
- 16.0 months median PFS by BICR at 240 mg dose in first-line EGFR PACC mutant NSCLC; 68.2% confirmed ORR at 240 mg.
- 41% (7/17) confirmed CNS complete response; 53% CNS ORR in CNS-evaluable patients by BICR.
- Safety consistent with prior data: no Grade 4/5 TRAEs, no discontinuations due to TRAEs; most common TRAEs diarrhea, elevated liver enzymes, rash.
- Firmonertinib 240 mg selected for pivotal Phase 3; ALPACCA trial enrollment expected to start H2 2025.

## SEC filing metadata
- accession: 0001104659-25-061375
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465925061375/0001104659-25-061375-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465925061375/tm2518615d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-061375
- JSON: https://secwatch.observer/filing/0001104659-25-061375.json
- Plain text: https://secwatch.observer/filing/0001104659-25-061375.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.